<?xml version='1.0' encoding='utf-8'?>
<document id="22788578"><sentence text="Drug interaction potential of resveratrol."><entity charOffset="30-41" id="DDI-PubMed.22788578.s1.e0" text="resveratrol" /></sentence><sentence text="Resveratrol is a naturally occurring polyphenol that is often used as a food supplement"><entity charOffset="0-11" id="DDI-PubMed.22788578.s2.e0" text="Resveratrol" /><entity charOffset="37-47" id="DDI-PubMed.22788578.s2.e1" text="polyphenol" /><pair ddi="false" e1="DDI-PubMed.22788578.s2.e0" e2="DDI-PubMed.22788578.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22788578.s2.e0" e2="DDI-PubMed.22788578.s2.e1" /></sentence><sentence text=" Many positive health effects, including cardio protection, tumor suppression, and immune modulation, are associated with the intake of resveratrol"><entity charOffset="136-147" id="DDI-PubMed.22788578.s3.e0" text="resveratrol" /></sentence><sentence text=" Resveratrol is well tolerated in healthy subjects without any comedication"><entity charOffset="1-12" id="DDI-PubMed.22788578.s4.e0" text="Resveratrol" /></sentence><sentence text=" However, supplemental doses of resveratrol in the range of 1 g/day or above by far exceed the natural intake through food"><entity charOffset="32-43" id="DDI-PubMed.22788578.s5.e0" text="resveratrol" /></sentence><sentence text=" Whether resveratrol-drug interactions can be harmful in patients taking additional medications remains unknown"><entity charOffset="9-20" id="DDI-PubMed.22788578.s6.e0" text="resveratrol" /></sentence><sentence text=" Recent in vivo studies and clinical trials indicate a possible drug-drug interaction potential using high-dosage formulations" /><sentence text=" In this review, the known in vitro and in vivo effects of resveratrol on various cytochrome P450 (CYP) isoenzymes are summarized"><entity charOffset="59-70" id="DDI-PubMed.22788578.s8.e0" text="resveratrol" /></sentence><sentence text=" They are discussed in relation to clinically relevant plasma concentrations in humans" /><sentence text=" We conclude that resveratrol may lead to interactions with various CYPs, especially when taken in high doses"><entity charOffset="18-29" id="DDI-PubMed.22788578.s10.e0" text="resveratrol" /></sentence><sentence text=" Aside from systemic CYP inhibition, intestinal interactions must also be considered" /><sentence text=" They can potentially lead to reduced first-pass metabolism, resulting in higher systemic exposure to certain coadministrated CYP substrates" /><sentence text=" Therefore, patients who ingest high doses of this food supplement combined with additional medications may be at risk of experiencing clinically relevant drug-drug interactions" /><sentence text="" /></document>